Increased Mortality and Healthcare Costs Upon Hospital Readmissions of Ulcerative Colitis Flares: A Large Population-Based Cohort Study

Simcha Weissman, DO,*†† Sachit Sharma, MD,† †† Brian M. Fung, MD,‡ Muhammad Aziz, MD,§ Michael Sciarra, DO,¶ Arun Swaminath, MD,|| and Joseph D. Feuerstein, MD**

*Department of Medicine, Hackensack Meridian Health Palisades Medical Center, North Bergen, New Jersey, USA
†Department of Medicine, University of Toledo Medical Center, Toledo, Ohio, USA
‡Division of Gastroenterology and Hepatology, University of Arizona College of Medicine—Phoenix, Phoenix, Arizona, USA
§Division of Gastroenterology, University of Toledo Medical Center, Toledo, Ohio, USA
¶Department of Gastroenterology and Hepatology, Hackensack Meridian Health Palisades Medical Center, North Bergen, New Jersey, USA
||Division of Gastroenterology, Inflammatory Bowel Disease Program, Lenox Hill Hospital, New York, New York, USA
**Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
††Co-first authors.

Address correspondence to: Simcha Weissman, DO, Department of Medicine, Hackensack Meridian Health Palisades Medical Center, 7600 River Road, North Bergen, NJ 07047, USA (simchaweissman@gmail.com).

Background: Ulcerative colitis (UC) flares often result in prolonged hospitalization and considerable mortality. Nevertheless, large-scale analyses evaluating the frequency and characteristics of hospital readmissions for UC remain limited. We aimed to examine these clinical outcomes in a nationwide cohort of patients hospitalized with UC.

Methods: We queried the 2017 Nationwide Readmission Database using ICD-10-CM codes to identify all adult patients admitted for UC. Outcomes including mortality, readmission rates, predictors of readmission and mortality, and healthcare usage were assessed. Multivariate analysis was used to adjust for potential confounders.

Results: From the 31,063 patients hospitalized for UC, 17.38% were readmitted within 30 days and 28.51% in 90 days. UC accounted for 28.17% and 29.82% of readmissions at 30 and 90 days, respectively. Compared to index admission, 30- and 90-day readmissions were characterized by significantly higher mortality (0.42% vs 1.99% and 1.65%, respectively), longer hospital stays (5.05 vs 6.62 and 6.04 days, respectively), and increased hospital cost ($49,999 vs $62,288 and $59,698, respectively) (all \( P < 0.01 \)). Numerous factors, including chronic steroid use [hazard ratio (HR) 1.35] and opioid use (HR 1.6, were independently associated with increased 30-day readmission (\( P < 0.01 \)). Numerous factors, including anxiety (HR 1.21) and venous thromboembolism (HR 5.39), were independently associated with increased 30-day mortality (\( P < 0.01 \)).

Conclusions: In a large cohort of patients hospitalized for UC, we found that readmission is associated with higher mortality and more lengthy/costly admissions. Additionally, we found independent associations for readmission and mortality that may help identify patients who can benefit from close postdischarge follow-up.

Lay Summary

By examining over 30,000 patients admitted for ulcerative colitis in the United States, rehospitalization was found to be associated with higher death rates and more lengthy/costly stays. Additionally, we found predictors of rehospitalization and death—to help identify high-risk patients.

Key Words: ulcerative colitis, inflammatory bowel disease, readmission, predictors, mortality

Introduction

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder mainly comprised of Crohn disease and ulcerative colitis (UC). During flares, symptoms can be severe enough to require hospitalization. In fact, it is estimated that 18%–25% of patients with UC require at least 1 hospitalization for UC during their lifespan.1 This, in tandem with an increasing worldwide incidence and prevalence of IBD, poses a substantial burden on healthcare resources.3–4 Despite improved and newer therapeutic modalities for the management of patients with IBD, acute UC flares often result in prolonged hospitalization and subsequently pose a risk of mortality.5 While the mortality rate in patients with IBD is generally thought to be low, large population-based studies evaluating inpatient mortality—particularly in regards to patients who are readmitted—is lacking.5,6 One could postulate that the risk of mortality may be higher in the subset of patients requiring hospital readmission. Indeed, most prior data on UC readmissions have been
from small study samples, case series, and single-center experiences.7–11 Herein, we aimed to perform a large, population-based study to identify rates of mortality and healthcare usage, as well as their predictors, in patients admitted for UC.

Methods

Data Source
In this retrospective cohort study, we queried the National Readmission Database (NRD) from January 2017 to November 2017. The NRD is the largest database of hospital readmissions in the United States and is derived from billing data submitted to statewide organizations based upon discharge abstracts. The NRD 2017 is nationally representative as it contains data from almost 18 million hospital stays (unweighted) in 2454 hospitals in 28 states, accounting for almost 60% of the US population. It contains deidentified clinical and nonclinical elements at both the patient- and hospital level using the International Classification of Diseases-10th revision (ICD-10) coding system.

Study Population
Patients with a primary diagnosis of UC during hospitalization (based on ICD-10 diagnostic codes K51.90 and K51.91) were included in the study. Patients were excluded if: (1) they were less than 18 years of age, (2) they were admitted electively, or (3) they were admitted within 30 days of the end of the fiscal year (as all patients were followed for at least 30 days upon discharge) (Fig. 1). All-cause mortality, length of stay (LOS), and cost during the index hospital admission were identified. Thereafter, these patients (who were discharged) in January of 2017 were followed until November 2017 to determine the percentage readmitted within 30 and 90 days. All-cause hospitalization mortality, LOS, and cost were again identified, now upon readmission. Patient demographic, hospital demographic, and other risk factors (based on ICD-10 codes) for readmission and mortality, along with the most common diagnoses/causes of readmission, were also recorded. We reviewed prior studies to help select and categorize diagnostic codes that would accurately identify patients with UC.12–14 Supplementary Table 1 for the ICD-10 codes used in the study.

Ethical Considerations
Institutional Review Board approval was not required for this study as it was performed using deidentified and nationally available data.

Study Variables
Patient demographics included age, sex, median household income, primary expected payer, and burden of comorbidities, assessed by the Charlson Comorbidity Index (CCI). Hospital demographics included hospital size (based on the number of beds), teaching status, region, and location.

Primary and Secondary Outcomes
The primary outcome was mortality rate during (1) index admission, (2) 30-, and (3) 90-day readmission. Secondary outcomes were: (1) rates of readmission, (2) causes for readmission, (3) risk factors associated with readmission and mortality, as well as (4) mean hospitalization LOS and costs.

Statistical Analysis
Statistical analyses were performed using STATA, version 16.1 (StataCorp, College Station, TX). Weighting of patient-level observations was implemented. Univariate analysis was initially performed to calculate unadjusted odds ratio and determine confounders significantly associated with the outcomes. Multivariate regression analysis was used to adjust for potential confounders. A multivariate regression model was then built by including all confounders that were found to be significant by univariate analysis, to calculate an adjusted odds ratio. Logistic regression was used for binary outcomes and linear regression was used for continuous outcomes. Proportions were compared using Fisher exact test, and continuous variables were compared using Student t test. All P values were 2-sided, with 0.05 as the threshold for statistical significance.

Results

Baseline Patient and Hospital Characteristics
A total of 31,063 adult patients with a principal diagnosis of UC (upon discharge) were included in the study. The mean age was 48.8 years, the majority of patients were female (53.79%), and Medicare (48.1%) was the primary payer insurance. Patients were predominantly admitted to large (56.5%) teaching hospitals (71.04%) in large metropolitan areas (61.3%) (Table 1).

Mortality Rates Upon Index Admission and Readmission
Upon multivariate analysis, when compared to mortality on index admission, mortality upon 30- and 90-day readmission was significantly higher (0.42% vs 1.99% and 1.65%, respectively, P < 0.01) (Fig. 2). Upon sensitivity analysis, to exclude the possibility of higher acuity on readmission (in general) as driving the mortality rates, we found that the 1708 patients readmitted for UC had a higher overall mortality (2.29% vs 1.87%, P < 0.05) as compared to the other (3663) readmitted patients.
Impact of UC on Readmission

Upon multivariate analysis, when compared to the index admission, 30-day readmissions were characterized by significantly longer mean LOS (5.05 vs 6.62 days, \( P < 0.01 \)) and higher mean hospitalization charges ($49,999 vs $62,288, \( P < 0.01 \)). As an aggregate, 30-day readmission accounted for an additional 35,481 inpatient days and $334 million in hospitalization cost nationally.

Upon multivariate analysis, when compared to the original index admission, 90-day readmissions were also characterized by significantly longer mean LOS (5.04 vs 6.04 days, \( P < 0.01 \)), and higher mean hospitalization charges ($49,036 vs $59,698, \( P < 0.01 \)).

Readmission Rates and Reasons for Readmission

Of the 30,903 patients discharged from their index hospitalization and followed for 30 days, 17.38% (5371) were readmitted (within 30 days). Of the 24,553 patients discharged from the index hospitalization and followed for 90 days, 28.51% (7001) were readmitted (within 90 days).

UC was the most common primary diagnosis at both 30-(31.8%) and 90-day (31.25%) readmission. Table 2 contains a list of the most common primary diagnoses at 30- and 90-day readmission.

Risk Factors Associated With Readmission

Upon multivariate analysis, higher CCI (hazard ratio (HR) 1.08, \( P < 0.01 \)), longer LOS (HR 1.01, \( P < 0.01 \)), chronic steroid use (HR 1.35, \( P < 0.01 \)), admission to a teaching hospital (HR 1.12, \( P < 0.05 \)), opioid use (HR 1.65, \( P < 0.01 \)), venous thromboembolism (VTE) (HR 1.35, \( P < 0.01 \)), and congestive heart failure (HR 1.34, \( P < 0.01 \)) were independently associated with increased 30-day readmission. In contrast, female sex (HR 0.90, \( P < 0.05 \)) was not associated with increased 30-day readmission.

Upon multivariate analysis, higher CCI (HR 1.09, \( P < 0.01 \)), longer LOS (HR 1.01, \( P < 0.01 \)), anxiety (HR 1.21, \( P < 0.01 \)), opioid use (HR 1.52, \( P < 0.01 \)), admission to a teaching hospital (HR 1.18, \( P < 0.01 \)), and discharge to other than home (HR 1.27, \( P < 0.01 \)) were independently associated with in-
increased 30-day readmission rate. In contrast, older age (>65) (HR 0.99, $P < 0.01$) was not associated with increased 90-day readmission. Table 3 for the risk factors independently associated with readmission.

**Risk Factors Associated With Mortality**

Upon multivariate analysis, longer LOS (HR 1.01, $P < 0.01$), higher CCI (HR 1.35, $P < 0.01$), anxiety (HR 1.21, $P < 0.01$), VTE (HR 5.39, $P < 0.01$), acute kidney injury (HR 4.92, $P < 0.01$), opioid use (HR 1.52, $P < 0.05$), admission to a teaching hospital (HR 1.18, $P < 0.05$), and discharge to other than home (HR 1.18, $P < 0.05$) were independently associated with increased 30-day mortality. In contrast, older age (HR 0.99, $P < 0.05$), was not associated with increased 30-day mortality.

Upon multivariate analysis, older age (HR 1.05, $P < 0.01$), higher CCI (HR 1.46, $P < 0.01$), end-stage renal disease (HR 3.62, $P < 0.05$), and acute kidney injury (HR 4.92, $P < 0.01$) were independently associated with increased 90-day mortality. Table 4 for the risk factors independently associated with mortality.

**Discussion**

In this retrospective cohort study using a large national database of hospital readmissions, we found that patients with UC who were readmitted within 30 or 90 days from their index hospitalization had a significantly higher mortality rate (over 4-fold higher) compared to that of their index hospitalization. Additionally, patients with UC had a significantly longer hospitalization and increased hospitalization costs on readmission. We also identified risk factors for 30- and 90-day readmission and mortality. Opioid use, chronic steroid use, VTE, congestive heart failure, hospitalization at a teaching hospital, and a higher number of comorbidities were identified as characteristics that were independently associated with an increased 30-day readmission, while Table 3 for the numerous risk factors that were found to be associated with 30- and 90-day readmission in patients admitted for ulcerative colitis (UC) flares.

| Risk Factors for 30-Day Readmission | HR     | $P$   |
|------------------------------------|--------|-------|
| CCI score                          | 1.08   | <0.01 |
| LOS                                | 1.01   | <0.01 |
| Chronic steroid use                | 1.35   | <0.01 |
| Teaching hospital status           | 1.12   | <0.05 |
| Opioid use                         | 1.65   | <0.05 |
| VTE                                | 1.35   | <0.05 |
| Congestive heart failure (CHF)     | 1.34   | <0.05 |
| Female sex                         | 0.90   | <0.05 |

| Risk Factors for 90-Day Readmission | HR     | $P$   |
|------------------------------------|--------|-------|
| CCI score                          | 1.09   | <0.01 |
| LOS                                | 1.01   | <0.01 |
| Anxiety                            | 1.21   | <0.01 |
| Opioid use                         | 1.52   | <0.01 |
| Teaching hospital status           | 1.18   | <0.01 |
| Discharge to other than home       | 1.27   | <0.01 |
| Older age (>65)                    | 0.99   | <0.01 |

The numerous risk factors that were found to be associated with 30- and 90-day mortality in patients admitted for ulcerative colitis (UC) flares.

| Risk Factors for 30-Day Mortality | HR     | $P$   |
|-----------------------------------|--------|-------|
| CCI score                         | 1.09   | <0.01 |
| LOS                               | 1.01   | <0.01 |
| Anxiety                           | 1.21   | <0.01 |
| VTE                               | 5.39   | <0.01 |
| Acute kidney injury (AKI)         | 4.92   | <0.01 |
| Teaching hospital status          | 1.18   | <0.05 |
| Opioid use                        | 1.52   | <0.05 |
| Discharge to other than home      | 1.18   | <0.05 |
| Older age                         | 0.99   | <0.05 |

| Risk Factors for 90-Day Mortality | HR     | $P$   |
|-----------------------------------|--------|-------|
| CCI score                         | 1.46   | <0.01 |
| End-stage renal disease (ESRD)    | 3.62   | <0.05 |
| AKI                               | 4.92   | <0.01 |
| Older age                         | 1.05   | <0.01 |

**Table 3.** The numerous risk factors that were found to be associated with 30- and 90-day readmission in patients admitted for ulcerative colitis (UC) flares.

**Table 4.** The numerous risk factors that were found to be associated with 30- and 90-day mortality in patients admitted for ulcerative colitis (UC) flares.

Bold text highlights statistical significance.
Impact of UC on Readmission

This has previously been well described, as patients with IBD have an increased risk of VTE, and patients with active disease are more likely to have VTE. Furthermore, patients with IBD are more likely to develop postdischarge VTE than non-IBD patients.

Pain control is an important aspect in the care of patients with IBD, with prior studies demonstrating that chronic pain is associated with an increased risk of readmission. A study by Hazratjee et al found that patients with IBD who were discharged without opioid analgesia were 2.2-fold more likely to be readmitted within 30 days. However, opioid use disorder has been associated with an increased risk of 30-day readmission. In our study, we found that chronic opioid use was a significant predictor of both 30- and 90-day readmission and 30-day mortality. Indeed, it appears that pain control is important, but care must be taken to prevent chronic opiate dependence. Reja et al found that 2.6% of patients with UC were readmitted within 1 year for opiate use disorder; the mean total charge for readmission for opiate use disorder was $41,291 and associated with a mortality of 0.57%.

Corticosteroids, while very effective for the short-term treatment of IBD, have also been associated with a significant risk of complications, especially when used in the long term. In fact, prior studies have found that past use of steroids is associated with a higher risk of readmission (odds ratio 1.90). Our study is consistent with this finding; we found the chronic use of steroids to be a significant predictor of 30-day readmission. However, we note that the short-term use of steroids was not evaluated in this study, and our findings cannot be generalized to the short-term use of steroids. Furthermore, it is unclear whether the higher rate of readmission for patients with steroid use is due to the use of steroids (and their associated adverse effects) or that steroid use is simply a surrogate for more aggressive and refractory disease. Regardless, steroids have been demonstrated to play an important role in the management of IBD flares and its use during index admission can decrease the risk of 30-day readmission.

We also found that anxiety was associated with 90-day readmission and 30-day mortality. Psychiatric comorbidities have previously been noted to increase the risk of readmission in many medical conditions, including IBD. However, the finding of increased risk of 30-day mortality is a little more puzzling. While it is unlikely that anxiety itself increases the risk of death, we hypothesize that anxiety may be associated with having other comorbidities, which we found to be associated with a higher risk of death. Anxiety has also been demonstrated to be associated with disease activity, though disease severity may not always correlate with mortality.

There are several strengths to our study. First, the use of a large national database provided the ability to draw conclusions that we believe are representative of the US population. Our study also looked at factors associated with inpatient mortality, which we believe has greater clinical significance than readmission rate alone. Furthermore, we looked at both 30- and 90-day readmission and mortality rate, which allows one to determine the persistence of each predictor over time.

We also acknowledge several limitations of our study. Although our study draws its strength from a large sample of patients, it relies on administrative codes which have the potential for misclassification of IBD diagnoses and misrepresentation of reason for hospital admission. A prior study on the use of ICD-9 codes found that ICD-9 codes have low accuracy when it comes to identifying IBD patients. While the accuracy of ICD-10 codes, which were used in this study, have not yet been studied, we reviewed previously published manuscripts on the topic to confidently include the most appropriate ICD codes. The NRD also does not record race or ethnicity, variables which have been previously demonstrated to play a role in the risk of hospital readmission; black patients with IBD have previously been found to have an increased risk for readmission. Also, our study is not able to measure what happens between hospitalizations, including the risk of death outside of the hospital and the impact of postdischarge follow-up, both of which would provide greater context to the results of this study. Finally, we acknowledge the fact that mortality upon readmission in many patients was due to other causes (other than the UC). However, this is unlikely to affect the overall results for several reasons. First, we only included the UC as a primary diagnosis, and yet over 30% were readmitted for UC. Second, other readmission diagnoses, such as sepsis, were likely to be (at least in some cases) a direct result of the UC. Third, upon sensitivity analysis, our results demonstrate that UC readmissions had higher mortality, as compared to all other readmissions. Hence, we conclude that UC upon readmission is associated with mortality and believed to be one of the major factors driving the increased mortality and hospital LOS/cost found.

In summary, our study highlights that patients with UC have a high rate of hospital readmission and a high rate of mortality, particularly upon readmission. We have also identified critical risk factors that may help decrease the risk of readmission and mortality, as well as reduce healthcare costs, in this important patient population.

Supplementary Material

Supplementary data are available at Crohn’s & Colitis 360 online.

Funding

None relevant to this submission.

Conflict of Interest Statement

None relevant to this submission.

Author Contributions

S.W. and S.S. assisted with data acquisition, analyses, and manuscript preparation. B.M.F. assisted with manuscript preparation, critically revised the manuscript, and provided input regarding methodology. S.W., M.A., M.S., A.S., and J.D.F. critically revised the manuscript and provided input regarding methodology. A.S. and J.D.F. provided direct supervision and guidance. S.W. is the article guarantor. All authors agree to the final version of this manuscript.

Data Availability

The data underlying this article are available in the article and in its online supplementary material.
References

1. Pola S, Patel D, Ramamoorthy S, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. *Clin Gastroenterol Hepatol*. 2012;10:1315–1325.e4.

2. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet*. 2017;390:2769–2778.

3. Bernstein CN, Longobardi T, Finlayson G, et al. Direct medical cost of managing IBD patients: a Canadian population-based study. *Inflamm Bowel Dis*. 2012;18:1498–1508.

4. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. *Gastroenterology*. 2008;135:1907–1913.

5. Bewtra M, Kaiser LM, TenHave T, et al. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. *Inflamm Bowel Dis*. 2013;19:599–613.

6. Falvey J, Greenwood R, Creed TJ, et al. Mortality in ulcerative colitis—what should we tell our patients? Three year mortality following admission for the treatment of ulcerative colitis: a 6 year retrospective case review. *Frontline Gastroenterol*. 2010;1:35–41.

7. Tinsley A, Nymagon S, Mathers B, et al. Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. *Scand J Gastroenterol*. 2015;50:1103–1109.

8. Hanslik TP, Tevis SE, Suwanabol PA, et al. Characterizing readmission in ulcerative colitis patients undergoing restorative proctocolectomy. *J Gastrointest Surg*. 2015;19:564–569.

9. Nguyen GC, Bollegala N, Chong CA. Factors associated with readmissions and outcomes of patients hospitalized for inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2014;12:1897–1904.e1.

10. Feuerstein JD, Jiang ZG, Belkin E, et al. Surgery for ulcerative colitis is associated with a high rate of readmissions at 30 days. *Inflamm Bowel Dis*. 2015;21:2130–2136.

11. Bernstein CN, Nabalambo A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. *Am J Gastroenterol*. 2006;101:110–118.

12. Sharma S, Weissman S, Mehta TI, et al. Role of hospital teaching status on outcomes of patients with inflammatory bowel disease: a nationwide analysis. *Dig Dis Sci*. 2021;66:2216–2226. doi:10.1007/s10620-020-06497-8. PMID: 32696235.

13. Hou JK, Tan M, Sridham RW, et al. Accuracy of diagnostic codes for identifying patients with ulcerative colitis and Crohn’s disease in the Veterans Affairs Health Care System. *Dig Dis Sci*. 2014;59:2406–2410.

14. Stepaniuk P, Bernstein CN, Nugent Z, et al. Characterization of inflammatory bowel disease in elderly hospitalized patients in a large central Canadian Health region. *Can J Gastroenterol Hepatol*. 2015;29:274–278.

15. Kruger AJ, Hinton A, Afzali A. Index severity score and early readmission predicts increased mortality in ulcerative colitis patients. *Inflamm Bowel Dis*. 2019;25:894–901.

16. Benuzzillo JG, Rasmussen KD, Kfoury AG, et al. Mortality after readmission among heart failure patients. *J Heart Lung Transplant*. 2014;33:S272.

17. Barnes EL, Kochar B, Long MD, et al. Modifiable risk factors for hospital readmission among patients with inflammatory bowel disease in a nationwide database. *Inflamm Bowel Dis*. 2017;23:875–881.

18. Mudireddy P, Scott F, Feathers A, et al. Inflammatory bowel disease: predictors and causes of early and late hospital readmissions. *Inflamm Bowel Dis*. 2017;23:1832–1839.

19. Poojary P, Saha A, Chauhan K, et al. Predictors of hospital readmissions for ulcerative colitis in the United States: a national database study. *Inflamm Bowel Dis*. 2017;23:347–356.

20. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol*. 2008;103:2272–2280.

21. Doshi R, Doshi S, Desai J, et al. Trends in hospitalization and in-hospital mortality with inflammatory bowel disease complicated by venous thromboembolism. *JGILPD*. 2017;4:1–8.

22. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. *Thromb Haemost*. 2001;85:430–434.

23. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. *Lancet*. 2010;375:657–663.

24. McCurdy JD, Kuenzig ME, Smith G, et al. Risk of venous thromboembolism after hospital discharge in patients with inflammatory bowel disease: a population-based study. *Inflamm Bowel Dis*. 2020;26:1761–1768.

25. Hazratjee N, Agito M, Lopez R, et al. Hospital readmissions in patients with inflammatory bowel disease. *Am J Gastroenterol*. 2013;108:1024–1032.

26. Charlaou P, Mohapatra S, Joshi T, et al. Opioid use disorder increases 30-day readmission risk in inflammatory bowel disease hospitalizations: a nationwide matched analysis. *J Crohns Colitis*. 2020;14:636–645.

27. Cohen-Mekelburg S, Rosenblatt R, Gold S, et al. The impact of opioid epidemic trends on hospitalised inflammatory bowel disease patients. *J Crohns Colitis*. 2018;12:1030–1035.

28. Reja M, Hajela N, Makar M, et al. One-year risk of opioid use disorder after index hospitalization for inflammatory bowel disease. *Int J Colorectal Dis*. 2020;35:2081–2087.

29. Waljee AK, Wittala WL, Govani S, et al. Corticosteroid use and complications in a US inflammatory bowel disease cohort. *PLoS One*. 2016;11:e0138017.

30. Christian KE, Jambaulikar GD, Hagan MN, et al. Predictors of early readmission in hospitalized patients with inflammatory bowel disease. *Inflamm Bowel Dis*. 2017;23:1891–1897.

31. Ahmedani BK, Solberg LI, Copeland LA, et al. Psychiatric comorbidity and 30-day readmissions for patients with inflammatory bowel disease—what should we tell our patients? Three year mortality following admission for the treatment of ulcerative colitis: a 6 year retrospective case review. *Frontline Gastroenterol*. 2010;1:35–41.

32. Byrne G, Rosenfeld G, Leung Y, et al. Prevalence of anxiety and depression in patients with inflammatory bowel disease. *Can J Gastroenterol Hepatol*. 2017;2017:e6496727. https://www.hindawi.com/journals/cjgh/2017/6496727/ (12 December 2020, date last accessed).

33. Gunnells DJ Jr, Morris MS, DeRussy A, et al. Racial disparities in readmissions for patients with inflammatory bowel disease (IBD) after colorectal surgery. *J Gastrointest Surg*. 2016;20:985–993.